According to the French newspaper lesechos, India's sunpharmaceuticals, zyduscadilahealthcare and torrent have developed generic drugs of acomplia. The company said that it only focuses on the Indian market at present, but also plans to list in other countries permitted by law or patents. It is reported that cadilahealthcare Company and torrent Company have started selling acomplia generic drugs under the trade names slimona and rimoslim in early May, and torrent Company expects that the sales revenue of this product will reach 654.38 billion rupees (2.5 million US dollars) this year.
It is understood that acomplia was approved to be listed in Europe in 2006 and is currently waiting for the approval of the US fda. The market potential of diet pills is huge, and this product will compete with Roche (Orlistat, Sanico) and Abbott (Sibutramine, Merida/Reduced Tall) for market share. Sanofi-Aventis has submitted an application to the Indian authorities to market the product, but it has not been approved yet. In other words, acomplia currently has no patent protection in the Indian market.
In this regard, Sanofi Aventis said that it would pursue legal responsibility. Acomplia means a lot to Sanofi-Aventis. At present, the company's three major products are facing competition from generic drugs, including enoxaparin (lovenox), zolpidem (ambien) and clopidogrel (plavix). The company has high hopes for this product and hopes to go public as soon as possible to promote performance growth. However, at present, acomplia's prospects are unpredictable, at least its Indian market has lost before the war.
The market is always full of competition, especially the market with huge profit space. Judging from the fact that acomplia generic drugs are listed before branded drugs, the R&D strength and market acumen of Indian generic drugs companies are amazing. We have to re-examine the definition of generic competition. This word, which once appeared only when the patent of brand-name drugs expired or was about to expire, has now been given a new meaning. Perhaps, generic drug companies will become competitors that brand pharmaceutical companies can't be underestimated. At least, Sanofi-Aventis has learned a lot.